- Home
- XBIO vs ACON Comparison
XBIO vs ACON Comparison
Compare XBIO & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBIO | ACON |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.4M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | XBIO | ACON |
|---|---|---|
| Price | $2.43 | $3.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 25.0K | ★ 2.4M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,858,935.00 | $67,483.00 |
| Revenue This Year | $1.99 | $71.77 |
| Revenue Next Year | $20.00 | $80.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.30 | ★ 36.91 |
| 52 Week Low | $1.90 | $3.68 |
| 52 Week High | $13.93 | $692.84 |
Technical Indicators
Market Signals| Indicator | XBIO | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 57.78 | 38.34 |
| Support Level | $2.20 | $4.32 |
| Resistance Level | $2.31 | $9.36 |
| Average True Range (ATR) | 0.10 | 0.60 |
| MACD | 0.05 | -0.14 |
| Stochastic Oscillator | 90.63 | 1.94 |
Price Performance
Historical ComparisonAbout XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.